This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Boot Barn and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boot Barn and Align Technology are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Align Technology (ALGN)
by Jeremy Mullin
Will this stock find the right alignment to avoid further decline?
ALGN Stock Rise on the Release of Invisalign Smile Architect Software
by Zacks Equity Research
Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.
ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Align Technology (ALGN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Align Technology (ALGN) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 1.73% and 1.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 3 MedTech Stocks Surpass Q3 Earnings Forecasts?
by Urmimala Biswas
Here is a sneak peek into how three MedTech stocks, BSX, TMO and ALGN, are expected to fare in their third-quarter results, slated to be released tomorrow.
Unveiling Align Technology (ALGN) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Align Technology (ALGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's third-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align Technology (ALGN) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align Technology (ALGN) Encounters Low ASP, FX Headwinds
by Zacks Equity Research
Align Technology's (ALGN) Clear Aligner ASP is facing a significant impact of unfavorable foreign exchange across multiple currencies.
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Align Technology (ALGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Align Technology (ALGN) Q2 Earnings Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 3.88% and 0.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Can These 4 MedTech Stocks Hit Targets This Earnings Season?
by Urmimala Biswas
Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.
Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Holding Align Technology (ALGN) Stock Could Pay Off
by Zacks Equity Research
Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
Buy These 5 Stocks on the Dip to Gain From Wall Street Rally
by Nalak Das
Five top stocks at attractive valuations are: DELL, OKTA, GPN, ALGN, RBLX.
Are Options Traders Betting On a Big Move In Align Technology (ALGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Align Technology (ALGN) stock based on the movements in the options market lately.
DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex
by Zacks Equity Research
DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.